Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 - ACR-2316 was internally discovered and advanced in 15 months...
September 14, 2024 03:10 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically...
September 10, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its...
September 09, 2024 07:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets...
August 13, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon...
May 29, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
May 14, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
April 24, 2024 16:01 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed overall...
April 16, 2024 20:01 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
April 10, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in...